HQ
Columbus, Ohio
Founded
2016
Founders and CEO
Robert Shalwitz, Founder and CEO
Sector
Life Sciences

Company Profile

Invirsa's lead compound, INV-102, is derived from a naturally occurring molecule that combats viral conjunctivitis (viral pinkeye) by enhancing the body's own ability to fight the disease.

Blogs About Invirsa

Invirsa Secures Seed Financing to Develop New Approach to Treating Common Infectious Diseases that Affect Millions Annually
Startup Buzz
Invirsa Secures Seed Financing to Develop New Approach to Treating Common Infectious Diseases that Affect Millions Annually
By Rev1 Staff on
Invirsa Develops Natural Compound to Treat Pinkeye
Startup Buzz
Invirsa Develops Natural Compound to Treat Pinkeye
By Mary Jane Grinstead on

Invirsa in the News

CincyTech Leads $7.7M Round for Columbus-Based Pharma Startup Invirsa
CincyTech Leads $7.7M Round for Columbus-Based Pharma Startup Invirsa
Federal contract for as much as $30M moves Columbus biotech on path to FDA approval
Company News
Federal contract for as much as $30M moves Columbus biotech on path to FDA approval
Invirsa is Developing a Drug for Viral Infection Treatment
CincyInno
Company News
Invirsa is Developing a Drug for Viral Infection Treatment
Invirsa Secures $520K in Seed Funding
Finsmes
Company News
Invirsa Secures $520K in Seed Funding
Drug developer Invirsa snags $520K
PE HUb
Company News
Drug developer Invirsa snags $520K